Lv1
60 积分 2025-02-17 加入
Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial
2天前
已完结
Thrombospondin-1 regulation of latent TGF-β activation: A therapeutic target for fibrotic disease
10天前
已完结
A Phase I Study of TRK-250, a Novel siRNA-Based Oligonucleotide, in Patients with Idiopathic Pulmonary Fibrosis
1个月前
已完结
Elevated TGF-β1 concentration in bronchoalveolar lavage fluid from patients with primary lung cancer
1个月前
已完结
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
1个月前
已完结
Elevated sL1‐CAM levels in BALF and serum of IPF patients
1个月前
已完结
Lung fibrosis-associated soluble mediators and bronchoalveolar lavage from idiopathic pulmonary fibrosis patients promote the expression of fibrogenic factors in subepithelial lung myofibroblasts
1个月前
已完结
Study of the cellular mechanism of Sunitinib mediated inactivation of activated hepatic stellate cells and its implications in angiogenesis
1个月前
已完结
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial
2个月前
已完结
Forced Vital Capacity in Idiopathic Pulmonary Fibrosis — FDA Review of Pirfenidone and Nintedanib
2个月前
已完结
皖公网安备34019202002308
